MD Anderson Cancer Center’s Post

Rare types of #cancer, such as those that affect children, are difficult to research due to small population sizes. The TRACER initiative by Dr. Taran Gujral at Fred Hutch is changing that by fostering collaboration between smaller labs, exploring drug repurposing and more. Read their guest blog for #RareCancerDay today! https://lnkd.in/emDqrAGN #RareCancer #Oncology #DrugRepurposing #RareDiseases Seattle Children's UW Medicine

Models based on global data predict that the number of early-onset #cancer cases will increase by around 30% between 2019 and 2030 Research is that field will be critical

https://lnkd.in/dT63dt8m Certainly a very worthwhile read. An evolving group of illness requires an equally evolving perspective from all of us, in our search to sufficiently understand & adapt to them.

The Knotty Ribbon problem of Prostate Carcinoma There is a concerning trend of increase in incidence of prostatic carcinoma that should not be ignored. Dubbed ‘the silent killer’, prostate cancer claimed 397,430 lives globally in 2022, according to the Global Cancer Observatory. A report published in The Lancet on April 4 revealed an even more unsettling projection: prostate cancer is set to escalate global morbidity and mortality. By 2040, cases are anticipated to double, the medical journal said. Worse, with a 30% nationwide surge and an annual influx of 42,000 new cases, India is expected to be among the worst affected countries in the world. Already, the numbers are staggering, with urban areas recording a 75%–80% spike in cases of prostate cancer over the last two-and-a-half decades. The primary reason for late-stage detection is the lack of awareness and early screening. The ribbon problem Have you noticed the light-blue ribbons that pop up every year around September? Those are meant to spread awareness about prostate cancer. However, the problem is that ribbons of various colours have become ubiquitous as the easiest medium for those trying to increase awareness about everything from road safety to climate change, not just cancers. Tracing back the ribbon takes us to Evelyn H Lauder, the Austrian American businessperson and philanthropist who was diagnosed with breast cancer in 1989. She embarked on a mission as an advocate for women’s health. Lauder initiated the groundbreaking pink ribbon campaign within Estée Lauder Companies. They distributed ribbons and self-exam instruction cards at Estée Lauder counters worldwide, sparking conversations, and raising awareness about breast health. Lauder founded the Breast Cancer Research Foundation, raising over USD350 million for global research, education, and medical services. Through this one initiative, breast cancer was brought to the forefront of public consciousness. Since then, the narrative surrounding breast cancer has undergone a profound transformation. Once a stigmatised disease dealt with quietly and in isolation, it has now emerged as a pressing public health issue worthy of widespread discussion and action. Mimicking the success of the breast cancer campaign isn’t merely about changing the hue of the ribbon. The pink ribbon campaign worked because it carried a clear message aimed at solving a specific problem for a well-defined audience. While learning from the success of the breast cancer campaigns is critical, it is also important to note that the messaging should be based on the need of the specific problem at hand. Instead, today ribbons have become the shorthand for cancer campaigns. Simply put, cancer has a big ribbon problem. Citation: https://lnkd.in/gU-y2xNu #prostatecancer #cancer #cancerawareness

Dr. Avital Gaziel, co-founder of our #client Leal Health, highlights the promise of personalized cancer vaccines in the fight against cancer. Read more about the innovative approach to tackling cancer in this compelling story: #CancerResearch #PersonalizedMedicine #AI #HealthTech

What are the two main factors in cancer treatment success? Find out what Sarah, who was diagnosed with breast cancer, had to learn the hard way... https://buff.ly/3yHZawh #KnowledgeIsPower #CancerTreatments #CancerCare #PrecisionCancerMedicine #CancerResearch

The UK is generally considered to have good access to cancer treatment and healthcare, in general. However, research suggests that it’s still facing issues. Compared to Norway, Australia, and Canada, the UK’s cancer survival rates are about 10-15 years behind, with fewer patients undergoing chemo and radiotherapy. These rates are still higher than the most underserved countries, but that doesn’t mean the UK should ignore the issue. Every patient deserves access to the highest quality of care, and they shouldn’t have to go to a different country to receive it. We must keep working to make cancer treatment accessible until high-quality care becomes available to everyone who might need it. #Oncology #Cancer #CancerTreatment #HealthInequality

What are the two main factors in cancer treatment success? Find out what Sarah, who was diagnosed with breast cancer, had to learn the hard way... https://buff.ly/3yHZawh #KnowledgeIsPower #CancerTreatments #CancerCare #PrecisionCancerMedicine #CancerResearch

Here's an update into my treatment, summing up the past month or so. This piece of writing follows on from the last post published on 2 March. It has been another interesting month for news and stories in the wider world about cancer diagnoses and further studies into cancer treatment. It's also about a song I've been working on. https://lnkd.in/eRXR3--w #playingfortime #bowelcancer #bowelcancerawarenessmonth

The journey of a cancer patient in Kenya can be winding and exhausting. Our newly published paper led by Rahma Mkuu documents experiences of cervical cancer patients treated at the Machakos Cancer Center and gives insights on what needs to be done to improve outcomes. https://lnkd.in/dHPNtfTP